- Home
- AKRO vs SKYW Comparison
AKRO vs SKYW Comparison
Compare AKRO & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- SKYW
- Stock Information
- Founded
- AKRO 2017
- SKYW 1972
- Country
- AKRO United States
- SKYW United States
- Employees
- AKRO N/A
- SKYW N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- SKYW Air Freight/Delivery Services
- Sector
- AKRO Health Care
- SKYW Consumer Discretionary
- Exchange
- AKRO Nasdaq
- SKYW Nasdaq
- Market Cap
- AKRO 3.5B
- SKYW N/A
- IPO Year
- AKRO 2019
- SKYW N/A
- Fundamental
- Price
- AKRO $40.48
- SKYW $87.37
- Analyst Decision
- AKRO Strong Buy
- SKYW Buy
- Analyst Count
- AKRO 9
- SKYW 4
- Target Price
- AKRO $76.29
- SKYW $109.75
- AVG Volume (30 Days)
- AKRO 938.9K
- SKYW 593.8K
- Earning Date
- AKRO 05-09-2025
- SKYW 04-24-2025
- Dividend Yield
- AKRO N/A
- SKYW N/A
- EPS Growth
- AKRO N/A
- SKYW 909.09
- EPS
- AKRO N/A
- SKYW 7.77
- Revenue
- AKRO N/A
- SKYW $3,527,920,000.00
- Revenue This Year
- AKRO N/A
- SKYW $11.60
- Revenue Next Year
- AKRO N/A
- SKYW $4.70
- P/E Ratio
- AKRO N/A
- SKYW $11.31
- Revenue Growth
- AKRO N/A
- SKYW 20.18
- 52 Week Low
- AKRO $17.86
- SKYW $64.61
- 52 Week High
- AKRO $58.40
- SKYW $135.57
- Technical
- Relative Strength Index (RSI)
- AKRO 36.69
- SKYW 39.40
- Support Level
- AKRO $41.84
- SKYW $88.42
- Resistance Level
- AKRO $45.38
- SKYW $96.81
- Average True Range (ATR)
- AKRO 1.98
- SKYW 3.39
- MACD
- AKRO -0.40
- SKYW 0.78
- Stochastic Oscillator
- AKRO 16.39
- SKYW 40.29
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.